Circulating plasmacytoid and myeloid dendritic cells in breast cancer patients

[1]  W. Woodward,et al.  Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer , 2016, Oncotarget.

[2]  S. Weinstein,et al.  Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial , 2016, Clinical Cancer Research.

[3]  L. Richter,et al.  CD1c-Expression by Monocytes – Implications for the Use of Commercial CD1c+ Dendritic Cell Isolation Kits , 2016, PloS one.

[4]  G. Pawelec,et al.  Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer , 2016, Journal of Translational Medicine.

[5]  M. Haniffa,et al.  Human and Mouse Mononuclear Phagocyte Networks: A Tale of Two Species? , 2015, Front. Immunol..

[6]  G. Pawelec,et al.  Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients , 2015, Breast Cancer Research.

[7]  Xuetao Cao,et al.  Intratumoral dendritic cells in the anti-tumor immune response , 2015, Cellular and Molecular Immunology.

[8]  C. Bachert,et al.  Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma , 2015, Journal of Translational Medicine.

[9]  F. Ginhoux,et al.  Monocytes and macrophages: developmental pathways and tissue homeostasis , 2014, Nature Reviews Immunology.

[10]  N. McGovern,et al.  Human dendritic cell subsets , 2013, Immunology.

[11]  F. Montemurro,et al.  Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Blay,et al.  Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3+ regulatory T cells and are associated with poor prognosis in breast cancer patients , 2013, Oncoimmunology.

[13]  R. Sorrentino,et al.  Plasmacytoid dendritic cells and their therapeutic activity in cancer , 2012, Oncoimmunology.

[14]  E. Frigimelica,et al.  Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. , 2009, Blood.

[15]  X. Qu,et al.  BDCA‐1+, BDCA‐2+ and BDCA‐3+ dendritic cells in early human pregnancy decidua , 2008, Clinical and experimental immunology.

[16]  C. Liu,et al.  Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells in the Induction of Antigen-Specific Antitumor Immune Responses , 2007, The Journal of Immunology.

[17]  R. Steinman.  Linking innate to adaptive immunity through dendritic cells. , 2008, Novartis Foundation symposium.

[18]  J. Blay,et al.  Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer , 2004, Clinical Cancer Research.

[19]  J. Roliński,et al.  Dendritic cells in peripheral blood of patients with breast and lung cancer--a pilot study. , 2004, Folia histochemica et cytobiologica.

[20]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[21]  Dnj Hart,et al.  Dendritic cell immunotherapy for cancer: Application to low‐grade lymphoma and multiple myeloma , 1999, Immunology and cell biology.

[22]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[23]  D. Hart,et al.  Dendritic cells: unique leukocyte populations which control the primary immune response. , 1997, Blood.

[24]  D. Carbone,et al.  Decreased antigen presentation by dendritic cells in patients with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.